# Nurami Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nurami-medical

- Industry: Medical Devices & Equipment
- Headquarters: Haifa, Israel
- Website: www.nurami-medical.com
- Total disclosed funding: $36M
- Latest round: Series B (Feb 13, 2025)
- Investors on record: 2

## About

Nurami Medical Ltd., based in Israel, specializes in advanced medical technology, focusing on innovative products for surgical applications, particularly in dural repair solutions.Founded in 2014 in Haifa, Israel, Nurami Medical Ltd. develops advanced medical solutions, notably the ArtiFascia® dural repair implant. Recent funding rounds have targeted operational scaling and product development. The company has successfully raised USD 30 mn in its Series B round on February 13, 2025, led by Almeda Ventures and participated by GlenRock Israel. The co-founders include Amir Bahar and Nora Nseir, with Hannoch Marksheid serving as CEO.Nurami specializes in advanced medical technology, with a primary focus on its flagship product, ArtiFascia®. This next-generation dural repair implant is designed to facilitate watertight closure and promote dura regeneration, utilizing a thin, pliable, biomimetic graft that is suturable and easy to handle. The innovative 2-in-1 design incorporates nanofibers that act as a biomimetic scaffold, enhancing the healing process, along with an integrated thin film that minimizes the risk of leaks. ArtiFascia® has successfully completed an 85-patient clinical study and is currently available in the U.S. market, having received 510k regulatory clearance. The primary customer base includes healthcare providers such as hospitals and surgical centers across the United States and other targeted international markets.Nurami operates on a business model that involves direct sales to healthcare facilities, hospitals, and surgical centers. The company’s flagship product, ArtiFascia®, is sold through a structured pricing plan that accommodates bulk purchases by medical institutions, allowing for streamlined procurement processes. Sales transactions are typically executed as direct-to-business agreements, where healthcare providers order the product based on their surgical needs. Nurami’s revenue is generated through these direct sales channels, which enables the company to establish close relationships with its clients while ensuring the availability of its advanced medical solutions to end users in emergency and elective surgical procedures.In February 2025, Nurami Medical Ltd. raised USD 30 mn in Series B funding, which will be utilized to expand its workforce and scale operations. The company plans to build a commercial manufacturing facility, a research and development lab, and clean rooms for producing its first FDA-approved product. Nurami is also targeting market expansion into new geographic regions, focusing on increasing its presence in international markets to enhance the adoption of its innovative medical solutions.

## Funding rounds

- Series B, Feb 13, 2025, $30M — GlenRock Israel, Almeda Ventures
- Series B, Nov 2, 2020, $6.2M — GlenRock Israel, Almeda Ventures

## Investors

- GlenRock Israel (https://capitalatlas.ai/funds/glenrock-israel) — Series B
- Almeda Ventures (https://capitalatlas.ai/funds/almeda-ventures) — Series B